Novo Nordisk A/S (NYSE:NVO) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Novo Nordisk A/S (NYSE:NVO) from a hold rating to a buy rating in a report published on Saturday.

Several other brokerages have also recently issued reports on NVO. BNP Paribas initiated coverage on shares of Novo Nordisk A/S in a research note on Tuesday, April 15th. They issued an “underperform” rating on the stock. Hsbc Global Res raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, April 28th. Guggenheim cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research note on Thursday, April 17th. Stifel Nicolaus cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. Finally, BMO Capital Markets reissued a “market perform” rating and issued a $64.00 price objective (down from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $112.00.

Novo Nordisk A/S Stock Down 3.5%

NVO stock opened at $77.02 on Friday. The company has a fifty day moving average price of $67.61 and a 200 day moving average price of $79.24. Novo Nordisk A/S has a 12 month low of $57.00 and a 12 month high of $148.15. The company has a market cap of $345.62 billion, a price-to-earnings ratio of 23.41, a price-to-earnings-growth ratio of 0.90 and a beta of 0.66. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, meeting the consensus estimate of $0.92. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. The firm had revenue of $11.87 billion during the quarter. Sell-side analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Hedge Funds Weigh In On Novo Nordisk A/S

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. M. Kulyk & Associates LLC grew its stake in shares of Novo Nordisk A/S by 3.9% during the 4th quarter. M. Kulyk & Associates LLC now owns 3,182 shares of the company’s stock worth $274,000 after purchasing an additional 119 shares during the period. Center for Financial Planning Inc. grew its stake in shares of Novo Nordisk A/S by 72.4% during the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock worth $25,000 after purchasing an additional 123 shares during the period. Tradewinds Capital Management LLC grew its stake in shares of Novo Nordisk A/S by 2.6% during the 4th quarter. Tradewinds Capital Management LLC now owns 4,984 shares of the company’s stock worth $429,000 after purchasing an additional 124 shares during the period. Exencial Wealth Advisors LLC grew its stake in shares of Novo Nordisk A/S by 0.5% during the 4th quarter. Exencial Wealth Advisors LLC now owns 23,094 shares of the company’s stock worth $1,987,000 after purchasing an additional 124 shares during the period. Finally, Indie Asset Partners LLC boosted its position in shares of Novo Nordisk A/S by 4.2% in the 4th quarter. Indie Asset Partners LLC now owns 3,128 shares of the company’s stock worth $269,000 after buying an additional 126 shares in the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.